Amicus Therapeutics (FOLD) Competitors $9.59 +0.07 (+0.74%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FOLD vs. BHC, ARWR, PRGO, TPTX, BBIO, EXEL, EXAS, RGEN, MDGL, and HALOShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), Turning Point Therapeutics (TPTX), BridgeBio Pharma (BBIO), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector. Amicus Therapeutics vs. Bausch Health Companies Arrowhead Pharmaceuticals Perrigo Turning Point Therapeutics BridgeBio Pharma Exelixis Exact Sciences Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Bausch Health Companies (NYSE:BHC) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Do institutionals & insiders hold more shares of BHC or FOLD? 78.7% of Bausch Health Companies shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, BHC or FOLD? Amicus Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Companies$8.76B0.34-$592M-$0.48-17.07Amicus Therapeutics$399.36M7.18-$151.58M-$0.34-28.21 Does the MarketBeat Community favor BHC or FOLD? Amicus Therapeutics received 169 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 73.44% of users gave Amicus Therapeutics an outperform vote while only 61.47% of users gave Bausch Health Companies an outperform vote. CompanyUnderperformOutperformBausch Health CompaniesOutperform Votes35961.47% Underperform Votes22538.53% Amicus TherapeuticsOutperform Votes52873.44% Underperform Votes19126.56% Do analysts recommend BHC or FOLD? Bausch Health Companies currently has a consensus target price of $7.75, suggesting a potential downside of 5.43%. Amicus Therapeutics has a consensus target price of $17.63, suggesting a potential upside of 83.79%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Bausch Health Companies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Amicus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Is BHC or FOLD more profitable? Bausch Health Companies has a net margin of -1.88% compared to Amicus Therapeutics' net margin of -21.21%. Amicus Therapeutics' return on equity of -15.97% beat Bausch Health Companies' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Companies-1.88% -755.86% 5.11% Amicus Therapeutics -21.21%-15.97%-3.17% Which has more risk & volatility, BHC or FOLD? Bausch Health Companies has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Does the media prefer BHC or FOLD? In the previous week, Amicus Therapeutics had 3 more articles in the media than Bausch Health Companies. MarketBeat recorded 5 mentions for Amicus Therapeutics and 2 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 1.19 beat Amicus Therapeutics' score of 0.66 indicating that Bausch Health Companies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Companies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmicus Therapeutics beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.87B$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-28.2110.61125.0817.74Price / Sales7.18243.751,182.0574.25Price / CashN/A22.1633.7232.53Price / Book17.445.474.684.68Net Income-$151.58M$153.61M$119.45M$226.08M7 Day Performance-7.52%-4.32%-2.46%-2.03%1 Month Performance-19.41%-8.61%-4.08%0.07%1 Year Performance-13.13%28.79%29.81%24.61% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.6577 of 5 stars$9.59+0.7%$17.63+83.8%-13.1%$2.84B$493.67M-28.21480BHCBausch Health Companies3.4347 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B-17.0720,270Positive NewsARWRArrowhead Pharmaceuticals3.5698 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$240.74M0.00400Upcoming EarningsAnalyst ForecastPRGOPerrigo4.9798 of 5 stars$27.15-0.3%$37.00+36.3%-10.8%$3.72B$4.66B0.009,140Positive NewsTPTXTurning Point TherapeuticsN/A$76.01flatN/A+0.0%$3.81B$30.83M-11.02250BBIOBridgeBio Pharma4.5782 of 5 stars$23.04+2.2%$47.57+106.5%-21.2%$4.35B$9.30M-9.56400Insider TradeAnalyst RevisionEXELExelixis4.7763 of 5 stars$34.65+0.7%$31.44-9.3%+65.6%$9.90B$2.08B22.211,310Insider TradeEXASExact Sciences4.8868 of 5 stars$52.70-2.3%$74.47+41.3%-21.7%$9.75B$2.50B-45.046,600Positive NewsRGENRepligen4.6338 of 5 stars$138.90+8.1%$190.25+37.0%-10.8%$7.20B$638.76M0.001,783Positive NewsMDGLMadrigal Pharmaceuticals3.7989 of 5 stars$317.09+0.9%$347.33+9.5%+66.8%$6.85BN/A-12.6490Analyst ForecastHALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.70B$829.25M15.15390Analyst Forecast Related Companies and Tools Related Companies BHC Alternatives ARWR Alternatives PRGO Alternatives TPTX Alternatives BBIO Alternatives EXEL Alternatives EXAS Alternatives RGEN Alternatives MDGL Alternatives HALO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FOLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
